INO Stock News: Inovio Pharmaceuticals Inc has room to rise amid two covid vaccine advantages


  • NASDAQ: INO is set to end the week with a steady upside gain.
  • Inovio Pharmaceuticals Inc is still in the COVID-19 vaccine race amid two major advantages. 
  • The pharma firm has other products in its pipeline which make it a potentially profitable long-term investment. 

With Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) try to beat each other with efficacy levels of their COVID-19 vaccines, it may be easy to forget about other efforts such as that of Inovio Pharmaceuticals Inc (NASDAQ: INO). The Plymouth Meeting, Pennsylvania-based pharma firm is also in the race to develop coronavirus immunization – a contest that may have more than one or two winners. 

Inovio has received permission to begin a Phase 2/3 trial called Innovate on November 16. While the firm's INO-4800's vaccine candidate needs two doses – like the others – it has other advantages. 

First, the inoculation can be stored at room temperature for a full year, easing its distribution and storage. Costs are also likely to be lower. Another factor in its favor – yet currently questioned by the regulator – is the ability to deliver the dose directly through the skin. Inovio's Cellectra 2000 device is needed for administering the vaccine, yet it is simpler than an outright injection. 

Inovio's Phase 1 trial has shown that the immunization candidate prompts the creation of both antibodies and T-cells. Even if the first vaccines that Americans and others receive do not come from Inovio, the easy storage and application of this protection could be used as a seasonal boost later on

Moreover, the company uses its DNA approach to develop other drugs. These include cancer, infectious disease, and human papillomavirus. That makes NASDAQ: INO a potential long-term investment. 

Inovio Pharmaceuticals Stock

NASDAQ: INO is quoted at $11.20 in Friday's pre-market trading. Shares are up some 1.63% after dropping by 0.1% on Thursday. Calm trading is relatively new to Inovio's shares, which have ranged between the $8 handle the $12 one during November. 

The firm is valued at $1.87 billion, making it a small company in comparison to other pharmaceutical firms. There is substantial room to go toward the 52-week high of $33.79. 

More 

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.

Feed news

Latest Forex News


Latest Forex News

Editors’ Picks

EUR/USD: Corrective pullback fades below previous support, 200-SMA

EUR/USD remains on the back foot, receding taking rounds to 1.2120-25, amid a sluggish Asian session trading on Wednesday. Sellers to keep reins as unless prices cross three-week-old resistance line. Easing bullish bias of MACD adds to the downside signals.

EUR/USD News

GBP/USD: Bears in control, cling to multi-day support near 1.4080

The GBP/USD pair started the session on Wednesday on a lower note. The pair recovered from the low of 1.4034 on Tuesday to close near the 1.4080 mark, where it waivers now. Momentum oscillator hints at downside momentum.

GBP/USD News

EUR/USD: Corrective pullback fades below previous support, 200-SMA

EUR/USD remains on the back foot, receding taking rounds to 1.2120-25, amid a sluggish Asian session trading on Wednesday. Sellers to keep reins as unless prices cross three-week-old resistance line. Easing bullish bias of MACD adds to the downside signals.

EUR/USD News

Shiba Inu ready to reverse to $0.0000050

SHIB price faces stiff resistance ahead. Shiba Inu has had a difficult time recovering, suggesting that it may soon face rejection. In the following video, FXStreet's analysts evaluate where SHIB price could be heading next as Shiba Inu gets weaker.

Read more

FOMC Preview: Taper talk and impact on dollar

The outcome of Wednesday’s Federal Reserve monetary policy announcement could set the stage for how the U.S. dollar and currencies trade over the next month. With that in mind, the greenback maintained its bid ahead of rate decision.

Read more

Forex MAJORS

Cryptocurrencies

Signatures